EBO CEO: New investment will support healthcare AI company’s international expansion

EBO CEO and Founder Gege Gatt has said a new investment from healthcare and life sciences investor Olea Venture Partners will support the company as it moves into its next stage of international growth.

The financial terms of the investment have not been disclosed.

Announced on Wednesday (1st October), the investment is intended to accelerate the adoption of EBO’s AI technology among healthcare providers, expand its use across additional clinical and operational workflows, and support further growth across Europe and into the United States.

Dr Gatt described the investment as a “vote of confidence” in EBO and the scale of the opportunity ahead.

“With Olea, we have a partner who understands that healthcare innovation succeeds through trust, evidence and disciplined execution,” he said.

“Together, we will help more healthcare organisations make patient access simpler, release capacity for their teams and adopt AI responsibly within the systems and safeguards they already rely on.”

EBO develops AI-powered technology aimed at automating patient interactions within healthcare organisations, including appointment management, self-assessments and communications along patient pathways.

The company currently has commercial operations in Malta, the UK, Italy and Greece and says it has 24 live deployments across UK NHS Trusts and hospitals.

Olea Venture Partners Founding and Managing Partner Dr Harietta Eleftherochorinou said EBO had demonstrated an ability to deploy its technology within complex healthcare environments.

According to figures provided by the companies, EBO has recorded patient adoption rates of up to 97 per cent and customer returns on investment of up to five times.

Olea Managing Partner Lampros Kourtis said the next stage would involve scaling EBO’s existing model.

Olea is expected to support the company as it increases adoption in the UK, strengthens its presence in Southeast Europe and enters the US market, particularly in areas including healthcare partnerships and commercial strategy.

The investment comes as EBO seeks to scale a platform already being used across several markets and clinical environments.